Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind …
K Reich, KA Papp, A Blauvelt, RG Langley… - The Lancet, 2021 - thelancet.com
Background There is an unmet need for a treatment for psoriasis that results in complete
skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody …
skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody …
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase …
KB Gordon, P Foley, JG Krueger, A Pinter, K Reich… - The Lancet, 2021 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …
Bimekizumab for the treatment of psoriasis: a review of the current knowledge
A Ruggiero, L Potestio, E Camela… - … : Targets and Therapy, 2022 - Taylor & Francis
Bimekizumab, a novel humanized monoclonal IgG1 antibody that neutralizes both IL-17A
and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in …
and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in …
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation
A Ruggiero, L Potestio, F Martora, A Villani… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Biological treatments deeply changed the management of moderate-to-severe
forms of psoriasis. Among the available biological therapies, interleukin (IL)-17 inhibitors …
forms of psoriasis. Among the available biological therapies, interleukin (IL)-17 inhibitors …
[HTML][HTML] Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
L Gargiulo, A Narcisi, L Ibba, A Balato, L Bianchi… - Frontiers in …, 2023 - frontiersin.org
Introduction Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F,
approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has …
approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has …
Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa …
R Oliver, JG Krueger, S Glatt, P Vajjah… - British journal of …, 2022 - academic.oup.com
Background Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin
(IL)‐17A and IL‐17F, which is currently under investigation for treatment of moderate‐to …
(IL)‐17A and IL‐17F, which is currently under investigation for treatment of moderate‐to …
[HTML][HTML] Bimekizumab versus secukinumab in plaque psoriasis
K Reich, RB Warren, M Lebwohl… - … England Journal of …, 2021 - Mass Medical Soc
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared …
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared …
[HTML][HTML] Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis
A Armstrong, K Fahrbach, C Leonardi… - Dermatology and …, 2022 - Springer
Introduction Biologic treatments are increasingly being used in the management of
moderate to severe plaque psoriasis (PSO). Bimekizumab is a selective inhibitor of both …
moderate to severe plaque psoriasis (PSO). Bimekizumab is a selective inhibitor of both …
First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
S Glatt, E Helmer, B Haier… - British journal of …, 2017 - Wiley Online Library
Aims To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly
UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL) …
UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL) …
[HTML][HTML] Bimekizumab versus adalimumab in plaque psoriasis
RB Warren, A Blauvelt, J Bagel, KA Papp… - … England Journal of …, 2021 - Mass Medical Soc
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-
17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the …
17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the …